Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand

Novavax raised its annual revenue forecast after beating quarterly expectations, helped by licensing-driven milestone payments that offset waning vaccine demand. The update signals improved near-term revenue visibility despite soft underlying demand trends.

Analysis

Novavax raised its annual revenue forecast after beating quarterly expectations, helped by licensing-driven milestone payments that offset waning vaccine demand. The update signals improved near-term revenue visibility despite soft underlying demand trends.